CMP 001 — Competitive Intelligence Brief

CMP 001 (cmp-001) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulatory Agent. Area: Oncology.

marketed Immunomodulatory Agent TLR9 Oncology

Target snapshot

CMP 001 (cmp-001) — Pfizer Inc..

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CMP 001 TARGET	cmp-001	Pfizer Inc.	marketed	Immunomodulatory Agent	TLR9
standard dose of HCQ	standard dose of HCQ	University of Sao Paulo General Hospital	marketed	Antimalarial immunosuppressant	Toll-like receptors (TLR7, TLR9); phospholipase C
SCH 697243	SCH 697243	ALK-Abelló A/S	phase 3	TLR9 agonist	TLR9
Hydroxychloroquine (HCQ)	Hydroxychloroquine (HCQ)	Post Graduate Institute of Medical Education and Research, Chandigarh	phase 3	Antimalarial immunomodulator	TLR7, TLR9, and lysosomal pH-dependent pathways
INT230-6	INT230-6	Intensity Therapeutics, Inc.	phase 3	TLR9 agonist immunotherapy	TLR9 (Toll-like receptor 9)
MGN1703 treatment	MGN1703 treatment	Mologen AG	phase 3	TLR9 agonist	TLR9
Ixazomib plus low-dose lenalidomide	Ixazomib plus low-dose lenalidomide	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Proteasome inhibitor and immunomodulatory agent	Proteasome and cereblon

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulatory Agent class)

1. Pfizer Inc. · 1 drug in this class